SK bioscience Co.,Ltd. (KRX: 302440)
South Korea
· Delayed Price · Currency is KRW 48,800
+800 (1.67%)
Feb 5, 2025, 12:04 PM KST
SK bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 201,300 | 369,506 | 456,726 | 929,001 |
| Other Revenue | 0 | - | -0 | - |
| Revenue | 201,300 | 369,506 | 456,726 | 929,001 |
| Revenue Growth (YoY) | -51.98% | -19.10% | -50.84% | - |
| Cost of Revenue | 146,940 | 227,681 | 217,443 | 358,968 |
| Gross Profit | 54,360 | 141,824 | 239,283 | 570,033 |
| Selling, General & Admin | 66,683 | 60,841 | 61,801 | 46,027 |
| Research & Development | 75,545 | 85,743 | 57,960 | 47,250 |
| Other Operating Expenses | 1,212 | 1,417 | 664.99 | 388.56 |
| Operating Expenses | 150,443 | 153,812 | 124,269 | 95,813 |
| Operating Income | -96,083 | -11,988 | 115,014 | 474,220 |
| Interest Expense | -975.65 | -1,398 | -2,461 | -3,427 |
| Interest & Investment Income | 8,112 | 13,555 | 4,854 | 1,517 |
| Currency Exchange Gain (Loss) | 1,357 | 13,325 | 16,506 | -1,662 |
| Other Non Operating Income (Expenses) | 490.12 | -18,722 | -28,620 | -434.77 |
| EBT Excluding Unusual Items | -87,099 | -5,228 | 105,293 | 470,212 |
| Gain (Loss) on Sale of Investments | 24,604 | 13,777 | 36,875 | 892.14 |
| Gain (Loss) on Sale of Assets | -110.19 | -68.06 | -434.6 | 23.62 |
| Asset Writedown | -1,154 | -1,154 | - | - |
| Pretax Income | -63,759 | 7,327 | 141,733 | 471,128 |
| Income Tax Expense | -20,484 | -14,990 | 19,281 | 115,989 |
| Net Income | -43,274 | 22,318 | 122,452 | 355,139 |
| Net Income to Common | -43,274 | 22,318 | 122,452 | 355,139 |
| Net Income Growth | - | -81.77% | -65.52% | - |
| Shares Outstanding (Basic) | 77 | 77 | 77 | 73 |
| Shares Outstanding (Diluted) | 77 | 77 | 77 | 74 |
| Shares Change (YoY) | -0.28% | -0.01% | 4.32% | - |
| EPS (Basic) | -563.33 | 290.65 | 1596.18 | 4844.07 |
| EPS (Diluted) | -565.42 | 290.00 | 1590.00 | 4810.00 |
| EPS Growth | - | -81.76% | -66.94% | - |
| Free Cash Flow | -183,759 | -14,114 | -197,951 | 493,686 |
| Free Cash Flow Per Share | -2392.11 | -183.27 | -2570.08 | 6686.61 |
| Gross Margin | 27.00% | 38.38% | 52.39% | 61.36% |
| Operating Margin | -47.73% | -3.24% | 25.18% | 51.05% |
| Profit Margin | -21.50% | 6.04% | 26.81% | 38.23% |
| Free Cash Flow Margin | -91.29% | -3.82% | -43.34% | 53.14% |
| EBITDA | -59,377 | 22,777 | 142,250 | 492,995 |
| EBITDA Margin | -29.50% | 6.16% | 31.15% | 53.07% |
| D&A For EBITDA | 36,706 | 34,765 | 27,236 | 18,775 |
| EBIT | -96,083 | -11,988 | 115,014 | 474,220 |
| EBIT Margin | -47.73% | -3.24% | 25.18% | 51.05% |
| Effective Tax Rate | - | - | 13.60% | 24.62% |
| Advertising Expenses | - | 1,849 | 1,190 | 1,909 |
Source: S&P Capital IQ. Standard template. Financial Sources.